Global Cancer Supportive Care Products Market, 2015 to 2021

Global Cancer Supportive Care Products Market, 2015 to 2021
Persistence Market Research
Global Cancer Supportive Care Products
Market to Account for US$ 31.7 Bn by 2021 :
Persistence Market Research
Persistence Market Research
1
Global Cancer Supportive Care Products Market, 2015 to 2021
Persistence Market Research Released New Market Report According to a new market report
published by Persistence Market Research “Global Cancer Supportive Care Products
Market: High consumption of Erythropoietin Stimulating Agents to drive the
market for Global Cancer Supportive Care Drugs,” the global cancer supportive care
products market is projected to expand at a CAGR of 4.3% during the forecast period (2015–
2021).
Cancer supportive care products are mainly used in the treatment of adverse effects
associated with cancer therapy as well as for treatment of symptoms and signs of cancer,
such as chemotherapy-induced nausea and vomiting, chemotherapy induced neutropenia
and anemia, bone metastasis, hair loss, etc. The cancer supportive care products market
accounted for US$ 23, 6002.0 Mn in 2014 and is expected to increase to US$ 31,700.0 Mn by
2021 at a CAGR of 4.3% over the forecast period.
The market for cancer supportive care products, though shrouded by the loss of brands
exclusivity of various generic drugs and entry of biosimilar drugs, presents lucrative
opportunity, as they offer ease of accessibility, affordability, and administration to potential
customers.
Request Customize Full TOC: http://www.persistencemarketresearch.com/toc/5336
The report analyzes the global cancer supportive care products market in terms of market
value (US$ Mn), by drug class, disease indication, region, and distribution channels, and
provides information regarding regional market dynamics, regulations, PEST analysis,
competitive landscape, current trends, market estimations, and forecast.
Among the drug class segments, erythropoietin stimulating agents, such as NeoRecormon,
Procrit, and Arsanep, are expected to account for the largest share of the global cancer
supportive care products market, followed by granulocyte colony-stimulating factors and
others. The erythropoietin stimulating agents segment is expected to gain traction in the
near future due to increasing number of patients suffering from chemotherapy-induced
neutropenia (low count of neutrophils). Increasing demand for high-quality cancer supportive
care products is also influencing manufacturers to opt for better quality active
Persistence Market Research
2
Global Cancer Supportive Care Products Market, 2015 to 2021
pharmaceutical ingredients and maintain a sterile microbial contamination-free
manufacturing space.
By disease indication type, the cancer supportive care products market is segmented into
various forms of cancers, such as lung cancer, breast cancer, prostate cancer, etc. Among
these, the lung cancer segment is expected to dominate the overall market in future, i.e. by
2021, owing to greater incidences of tobacco smoking cases, rising pollution, and exposure
to harmful chemicals and gases released from various industries. The segment is projected
to expand at a substantial growth rate over the forecast period. However, breast cancer is
also gaining traction due to changing lifestyle, the rise in adoption of hormone replacement
therapy, and genetic inheritance of genes such as BRCA1 and BRCA2.
Request Sample Report: http://www.persistencemarketresearch.com/samples/5336
Browse the full Global Cancer Supportive Care Products Market: High consumption of
Erythropoietin Stimulating Agents to drive the market for Global Cancer Supportive Care
Drugs report at http://www.persistencemarketresearch.com/market-research/cancersupportive-care-products-market.asp
Key market participants covered in the report include Amgen Inc., Johnson & Johnson,
Novartis Ag., Baxter International Inc, Fagron Group BV, Teva Pharmaceuticals Industries Ltd,
Hoffmann LA- Roche Ltd, APR Applied Pharma Science Research S.A., Acacia Pharma Ltd, and
Kyowa Hakko Kirin Co Ltd.
View Detail Report: http://www.persistencemarketresearch.com/market-research/cancersupportive-care-products-market.asp
The cancer supportive care products market is segmented as follows:
By Drug Class

Non-steroidal anti-inflammatory drugs

Anti-infective
Persistence Market Research
3
Global Cancer Supportive Care Products Market, 2015 to 2021

Anti-emetics

Monoclonal antibodies

Erythropoietin stimulating agents

Opioid analgesics

Bisphosphonates

Granulocyte colony stimulating factors
By Disease Indication

Lung cancer

Breast cancer

Prostate cancer

Liver cancer

Bladder cancer

Leukemia

Ovarian cancer

Melanoma

Others
By Distribution Channel

Hospital pharmacies

Retail pharmacies

Compounding pharmacies
By Region

North America

Latin America

Europe
Persistence Market Research
4
Global Cancer Supportive Care Products Market, 2015 to 2021

Asia Pacific

The Middle East & Africa
Market History:
Progress in cancer treatment procedures, with it, has brought challenges that go beyond
cure. Toxicity and morbidity are among the biggest hurdles that a cancer patient has to face
while undergoing chemotherapy or radiation therapy. Host of path-breaking technological
advancements have been made in the science of supportive care for treating chemotherapy
induced side effects, such as bone metastasis, cancer pain, oral mucositis, chemotherapy
induced neutropenia, chemotherapy induced nausea and vomiting, chemotherapy induced
anemia, and various signs and symptoms associated with it. Cancer supportive care
products or drugs are used in the treatment of side effects as well as various signs and
symptoms associated with chemotherapy. Drugs used for the treatment of chemotherapy
induced side effects belong to one of the drug classes mentioned below: non-steroidal antiinflammatory drugs, anti-infective, anti-emetics, monoclonal antibodies, erythropoietin
stimulating agents, opioid analgesics, bisphosphonates, and granulocyte colony stimulating
factors.
Globally, cancer supportive care products market is estimated to account for a market value
of US$ 24,620 Mn by the end of 2015, and it is projected to witness stable growth across all
global regions, due to rising incidences of cancer, leading to increasing demand for effective
cancer supportive care products.
The primary growth driver for the cancer supportive care products market are the rising
incidences of various forms of cancers worldwide. According to Globocan 2012, there were
14.1 Mn cancer cases estimated worldwide in 2012. Lung cancer was seen to be the most
common cancer worldwide among men, accounting for nearly 17% of the total number of
new cases diagnosed in 2012. Furthermore, greater effectiveness of anti-cancer drugs, such
as anti-emetics drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), opioid analgesics
drugs, etc., has been driving the growth of the global cancer supportive care products
market over the last few years. These drugs help prevent side-effects of cancer treatment on
the patient, due to which adoption rate of these cancer supportive care drugs has been on
the rise.
Persistence Market Research
5
Global Cancer Supportive Care Products Market, 2015 to 2021
Manufacturers of cancer supportive care products are more focused on innovation and
development of new drugs to maintain a competitive advantage in the market. Many
manufacturers have introduced various new drugs for the treatment of cancer and for
therapeutic approaches, including preventive vaccines and cancer supportive care products.
Over the last two years, 21 new molecular entities have been launched. These new
medicines have increased the possibility of treating cancer, leading to more combination
therapies and additional lines of therapy.
The rise in overall healthcare expenditure is also expected to contribute to the overall
growth of the cancer supportive care products market in the coming years. Healthcare
expenditure in the U.S. is projected to grow at an average annual rate of 5.8% during the
forecast period. By 2022, healthcare spending in the country is projected to account for
around 19.9% of its GDP. This is expected to boost the overall healthcare spending by
patients suffering from cancer in the country.
Globally, the market in North America is expected to expand at the strongest CAGR in terms
of value throughout the forecast period. The U.S. market in North America is estimated to
witness a single digit growth during the forecast period. Higher healthcare spending and
rising number of initiatives by the government to improve access to various drugs and
increase adherence, along with direct-to-consumer marketing in the U.S., are factors that are
expected to continue to further drive demand for the cancer supportive care products and,
thus, lead to standardization of the market in the region. Currently, erythropoietin
stimulating agents segment dominates the region in terms of drug class popularity.
However, cost issues and lack of reimbursement policies are expected to slightly hamper the
growth of the market in North America during the forecast period.
Europe is the second-most lucrative destination for cancer supportive care products
currently. Absence of post-treatment patient care in Eastern Europe is expected to affect the
overall market for supportive cancer care products in the region over the next few years.
The Europe market is expected to expand at a stable CAGR over the forecast period. Major
companies based in Europe are looking to expand their base outside Europe to better cater
to growing global demand for cancer supportive care products.
Persistence Market Research
6
Global Cancer Supportive Care Products Market, 2015 to 2021
Brazil is expected to contribute the largest market share in the Latin America cancer
supportive care product market and is expected to witness stable growth in terms of market
value during the forecast period. However, late diagnosis of cancer that leads to
epidemiological transition, wherein the cancer shifts from being an infectious disease to a
chronic disease, is a factor expected to restrict the growth of the overall cancer supportive
care products market in Latin America.
Globally, the Asia-Pacific market is expected to expand at the highest CAGR, followed by
North America, Europe, and Latin America. The Middle East & Africa accounts for a nominal
share of the overall cancer supportive care products market currently but is expected to
evolve over time with the expansion of infrastructural healthcare facilities and skill base of
pharmacists in the region.
Key market participants covered in the report include Amgen Inc., Johnson & Johnson,
Novartis Ag., Baxter International Inc, Fagron Group BV, Teva Pharmaceuticals Industries Ltd,
Hoffmann LA- Roche Ltd, APR Applied Pharma Science Research S.A., Acacia Pharma Ltd, and
Kyowa Hakko Kirin Co Ltd.
Persistence Market Research
7
Global Cancer Supportive Care Products Market, 2015 to 2021
About Us:
Persistence Market Research (PMR) is a full-service market intelligence firm specializing in syndicated
research, custom research, and consulting services. PMR boasts market research expertise across the
Healthcare, Chemicals and Materials, Technology and Media, Energy and Mining, Food and Beverages,
Semiconductor and Electronics, Consumer Goods, and Shipping and Transportation industries. The
company draws from its multi-disciplinary capabilities and high-pedigree team of analysts to share data
that precisely corresponds to clients’ business needs.
Contact Us:
Addie Thomes
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: 800-961-0353
Email: [email protected]
Web: http://www.persistencemarketresearch.com
Persistence Market Research
8